Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Watzka

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Thrombosis and Haemostasis|September 13, 2007
Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 allelesJohannes Oldenburg, Carville G Bevans, Andreas Fregin, et al.
Thrombosis Research|March 10, 2015
Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brainMichael Caspers, Katrin J Czogalla, Kerstin Liphardt, et al.
Biochimica Et Biophysica Acta|April 27, 2013
Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assayCarville G Bevans, Christoph Krettler, Christoph Reinhart, et al.
Nature Structural & Molecular Biology|December 13, 2016
Warfarin and vitamin K compete for binding to Phe55 in human VKORKatrin J Czogalla, Arijit Biswas, Klara Höning, et al.
Blood Advances|March 28, 2018
VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sitesKatrin J Czogalla, Kerstin Liphardt, Klara Höning, et al.
Thrombosis and Haemostasis|June 6, 2007
Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern GermansMatthias Watzka, Almut Nebel, Nour Eddine El Mokhtari, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 8, 2008
The first case of combined coagulation factor V and coagulation factor VIII deficiency in Poland due to a novel p.Tyr135Asn missense mutation in the MCFD2 geneVytautas Ivaskevicius, Jerzy Windyga, Beata Baran, et al.
Blood|August 29, 2013
Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfacesKatrin J Czogalla, Arijit Biswas, Ann-Christin Wendeln, et al.
BMC Pediatrics|September 3, 2014
Genetic variants of the vitamin K dependent coagulation system and intraventricular hemorrhage in preterm infantsChristine Schreiner, Sévérine Suter, Matthias Watzka, et al.
Thrombosis and Haemostasis|November 8, 2005
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulationChristof Geisen, Matthias Watzka, Katja Sittinger, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Thrombosis and Haemostasis|September 13, 2007
Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 allelesJohannes Oldenburg, Carville G Bevans, Andreas Fregin, et al.
Thrombosis Research|March 10, 2015
Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brainMichael Caspers, Katrin J Czogalla, Kerstin Liphardt, et al.
Biochimica Et Biophysica Acta|April 27, 2013
Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assayCarville G Bevans, Christoph Krettler, Christoph Reinhart, et al.
Nature Structural & Molecular Biology|December 13, 2016
Warfarin and vitamin K compete for binding to Phe55 in human VKORKatrin J Czogalla, Arijit Biswas, Klara Höning, et al.
Blood Advances|March 28, 2018
VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sitesKatrin J Czogalla, Kerstin Liphardt, Klara Höning, et al.
Thrombosis and Haemostasis|June 6, 2007
Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern GermansMatthias Watzka, Almut Nebel, Nour Eddine El Mokhtari, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 8, 2008
The first case of combined coagulation factor V and coagulation factor VIII deficiency in Poland due to a novel p.Tyr135Asn missense mutation in the MCFD2 geneVytautas Ivaskevicius, Jerzy Windyga, Beata Baran, et al.
Blood|August 29, 2013
Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfacesKatrin J Czogalla, Arijit Biswas, Ann-Christin Wendeln, et al.
BMC Pediatrics|September 3, 2014
Genetic variants of the vitamin K dependent coagulation system and intraventricular hemorrhage in preterm infantsChristine Schreiner, Sévérine Suter, Matthias Watzka, et al.
Thrombosis and Haemostasis|November 8, 2005
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulationChristof Geisen, Matthias Watzka, Katja Sittinger, et al.
Pageof 4